Randomised trial of fluoxetine and cognitive-behavioural therapy (CBT) versus fluoxetine alone in adolescents with persistent major depression (MD).

ISRCTN ISRCTN83809224
DOI https://doi.org/10.1186/ISRCTN83809224
Secondary identifying numbers HTA 97/29/01
Submission date
25/04/2003
Registration date
25/04/2003
Last edited
01/07/2013
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English Summary

Not provided at time of registration

Contact information

Prof Ian Goodyer
Scientific

Department of Child and Adolescent Psychiatry
University of Cambridge
Douglas House
18b Trumpington Road
Cambridge
CB2 2AH
United Kingdom

Phone +44 (0)122 333 6098/99
Email ig104@cam.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific title
Study hypothesisThe main objective is to test the principal hypothesis that the additional costs of Cognitive Behavioural Therapy (CBT) will be offset by improvements in patient outcomes and quality of life, and/or savings in the use of other health services, compared with fluoxetine alone. Other objectives are to determine whether the treatments differ (a) at follow-up, (b) in respect of other outcomes such as comorbid mental health problems and child/parent satisfaction, (c) within subgroups defined by severity.
Ethics approval(s)Not provided at time of registration
ConditionMental and behavioural disorders: Depression, anxiety, neuroses
InterventionPlease note that, as of 17 January 2008, the end date of this trial was updated from 31 October 2003 to 31 May 2005.

Interventions:
Because 1/4 cases of early onset depression remit rapidly, all cases will complete a brief initial educational/supportive intervention, and only those who still have major depression (MD) after 2 weeks will be randomised to CBT and fluoxetine or fluoxetine (stratified by severity). The design and execution of the trial, including telephone randomisation, will be supervised by the Health Care Trials Unit in Manchester (MCR) and the results will be reported in line with the CONSORT guidance.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Fluoxetine
Primary outcome measureCost and outcome measurement: Costs of the treatments to NHS and non-NHS services will be assessed with measures developed collaboratively by the Department of Health Economics in York and by Harrington's team in MCR in two clinical trials, one of which involved adolescents who had deliberately poisoned themselves (of whom >60% had MD). Clinical effectiveness and consumer views will be assessed using a range of standardised measures at 6 weeks, at 12 weeks, and at 6 months follow-up. The primary outcome will be a clinical measure of global functioning, the Health of the Nation Outcome Scale for Children and Adolescents (HoNOSCA).
Secondary outcome measuresOther measures will include remission from depression, comorbid problems and adverse effects. Vigorous efforts will be made to ensure that outcomes are assessed without knowledge of treatment group.
Overall study start date01/09/2000
Overall study end date31/05/2005

Eligibility

Participant type(s)Patient
Age groupChild
Lower age limit11 Years
Upper age limit17 Years
SexBoth
Target number of participants200
Participant inclusion criteriaAdolescents aged 11 through 17 years with mental disorders
Participant exclusion criteriaNot provided at time of registration
Recruitment start date01/09/2000
Recruitment end date31/05/2005

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Department of Child and Adolescent Psychiatry
Cambridge
CB2 2AH
United Kingdom

Sponsor information

Department of Health (UK)
Government

Quarry House
Quarry Hill
Leeds
LS2 7UE
United Kingdom

Phone +44 (0)1132 545 843
Email Sheila.Greener@doh.gsi.gov.uk
Website http://www.dh.gov.uk/en/index.htm
ROR logo "ROR" https://ror.org/03sbpja79

Funders

Funder type

Government

NIHR Health Technology Assessment Programme - HTA (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 21/07/2007 Yes No
Results article results 29/01/2008 Yes No
Results article results 01/05/2008 Yes No
Results article results 01/01/2013 Yes No